Gastrointestinal Cancer

The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E­–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses investigational treatment approaches in advanced pancreatic cancer.

The FDA’s Oncologic Drugs Advisory Committee voted 7 to 5 in favor of olaparib tablets for an indication as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.

Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

A new drug application has been submitted to the FDA for ripretinib for use as a treatment for patients with advanced gastrointestinal stromal tumors who have previously received treatment with imatinib, sunitinib, and regorafenib.

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for December 17, 2019, to discuss a supplemental new drug application for olaparib tablets as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.